The interaction between urokinase receptor and vitronectin in cell adhesion and signalling

European Journal of Cell Biology

Volumn 87, Issue 8-9, 2008, Pages 617-629

  Madsen, Chris D ^a   Sidenius, Nicolai ^a,b  

^a FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Cell adhesion; Cell migration; Fibronectin; Integrin signalling; Integrins; uPAR; Vitronectin

Indexed keywords

COLLAGEN; FIBRONECTIN; INTEGRIN; MATRIX METALLOPROTEINASE; PLASMINOGEN; PROTEINASE; UROKINASE RECEPTOR; VITRONECTIN;

CARCINOGENESIS; CELL ADHESION; CELL COMMUNICATION; EMBRYO DEVELOPMENT; EXTRACELLULAR MATRIX; HOMEOSTASIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; INFLAMMATION; LEUKOCYTE FUNCTION; MOLECULAR DYNAMICS; MORPHOGENESIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; REGULATORY MECHANISM; SHORT SURVEY; SIGNAL TRANSDUCTION; VIRUS REPLICATION; WOUND HEALING;

ANIMALS; CELL ADHESION; EXTRACELLULAR MATRIX; FOCAL ADHESIONS; HIV-1; HUMANS; INTEGRINS; MODELS, BIOLOGICAL; RECEPTORS, CELL SURFACE; SIGNAL TRANSDUCTION; VITRONECTIN;

EID: 49049092569     PISSN: 01719335     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejcb.2008.02.003     Document Type: Short Survey

References (103)

1. Aguirre Ghiso J.A. Inhibition of FAK signaling activated by urokinase receptor induces dormancy in human carcinoma cells in vivo. Oncogene 21 (2002) 2513-2524
2. Aguirre Ghiso J.A., Kovalski K., and Ossowski L. Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling. J. Cell Biol. 147 (1999) 89-104
3. Aguirre-Ghiso J.A., Liu D., Mignatti A., Kovalski K., and Ossowski L. Urokinase receptor and fibronectin regulate the ERK(MAPK) to p38(MAPK) activity ratios that determine carcinoma cell proliferation or dormancy in vivo. Mol. Biol. Cell 12 (2001) 863-879
4. Alfano M., Sidenius N., Panzeri B., Blasi F., and Poli G. Urokinase-urokinase receptor interaction mediates an inhibitory signal for HIV-1 replication. Proc. Natl. Acad. Sci. USA 99 (2002) 8862-8867
5. Artym V.V., Kindzelskii A.L., Chen W.T., and Petty H.R. Molecular proximity of seprase and the urokinase-type plasminogen activator receptor on malignant melanoma cell membranes: dependence on beta1 integrins and the cytoskeleton. Carcinogenesis 23 (2002) 1593-1601
6. Bershadsky A., Kozlov M., and Geiger B. Adhesion-mediated mechanosensitivity: a time to experiment, and a time to theorize. Curr. Opin. Cell Biol. 18 (2006) 472-481
7. Blasi F., and Carmeliet P. uPAR: a versatile signalling orchestrator. Nat. Rev. Mol. Cell Biol. 3 (2002) 932-943
8. Brooks P.C., Clark R.A., and Cheresh D.A. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 264 (1994) 569-571
9. Brooks P.C., Montgomery A.M., Rosenfeld M., Reisfeld R.A., Hu T., Klier G., and Cheresh D.A. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 79 (1994) 1157-1164
10. Brooks P.C., Stromblad S., Klemke R., Visscher D., Sarkar F.H., and Cheresh D.A. Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. J. Clin. Invest. 96 (1995) 1815-1822
11. Bugge T.H., Suh T.T., Flick M.J., Daugherty C.C., Romer J., Solberg H., Ellis V., Dano K., and Degen J.L. The receptor for urokinase-type plasminogen activator is not essential for mouse development or fertility. J. Biol. Chem. 270 (1995) 16886-16894
12. Carmeliet P., Moons L., Lijnen R., Baes M., Lemaitre V., Tipping P., Drew A., Eeckhout Y., Shapiro S., Lupu F., and Collen D. Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation. Nat. Genet. 17 (1997) 439-444
13. Chaurasia P., Aguirre-Ghiso J.A., Liang O.D., Gardsvoll H., Ploug M., and Ossowski L. A region in urokinase plasminogen receptor domain III controlling a functional association with alpha5beta1 integrin and tumor growth. J. Biol. Chem. 281 (2006) 14852-14863
14. Ciambrone G.J., and McKeown-Longo P.J. Vitronectin regulates the synthesis and localization of urokinase-type plasminogen activator in HT-1080 cells. J. Biol. Chem. 267 (1992) 13617-13622
15. Cunningham O., Andolfo A., Santovito M.L., Iuzzolino L., Blasi F., and Sidenius N. Dimerization controls the lipid raft partitioning of uPAR/CD87 and regulates its biological functions. EMBO J. 22 (2003) 5994-6003
16. Daci E., Udagawa N., Martin T.J., Bouillon R., and Carmeliet G. The role of the plasminogen system in bone resorption in vitro. J. Bone Miner. Res. 14 (1999) 946-952
17. Daci E., Everts V., Torrekens S., Van Herck E., Tigchelaar-Gutterr W., Bouillon R., and Carmeliet G. Increased bone formation in mice lacking plasminogen activators. J. Bone Miner. Res. 18 (2003) 1167-1176
18. Dano K., Behrendt N., Hoyer-Hansen G., Johnsen M., Lund L.R., Ploug M., and Romer J. Plasminogen activation and cancer. Thromb. Haemost. 93 (2005) 676-681
19. De Wever O., and Mareel M. Role of tissue stroma in cancer cell invasion. J. Pathol. 200 (2003) 429-447
20. Declerck P.J., De Mol M., Alessi M.C., Baudner S., Paques E.P., Preissner K.T., Muller-Berghaus G., and Collen D. Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin). J. Biol. Chem. 263 (1988) 15454-15461
21. Degryse B., Resnati M., Czekay R.P., Loskutoff D.J., and Blasi F. Domain 2 of the urokinase receptor contains an integrin-interacting epitope with intrinsic signaling activity: generation of a new integrin inhibitor. J. Biol. Chem. 280 (2005) 24792-24803
22. Deng G., Curriden S.A., Wang S., Rosenberg S., and Loskutoff D.J. Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release?. J. Cell Biol 134 (1996) 1563-1571
23. Edwards S., Lalor P.F., Tuncer C., and Adams D.H. Vitronectin in human hepatic tumours contributes to the recruitment of lymphocytes in an alpha v beta3-independent manner. Br. J. Cancer 95 (2006) 1545-1554
24. Elia C., Cassol E., Sidenius N., Blasi F., Castagna A., Poli G., and Alfano M. Inhibition of HIV replication by the plasminogen activator is dependent on vitronectin-mediated cell adhesion. J. Leuk. Biol. 82 (2007) 1212-1220
25. Emile J.F., Adam R., Sebagh M., Marchadier E., Falissard B., Dussaix E., Bismuth H., and Reynes M. Hepatocellular carcinoma with lymphoid stroma: a tumour with good prognosis after liver transplantation. Histopathology 37 (2000) 523-529
26. Furlan F., Galbiati C., Jorgensen N.R., Jensen J.E., Mrak E., Rubinacci A., Talotta F., Verde P., and Blasi F. Urokinase plasminogen activator receptor affects bone homeostasis by regulating osteoblast and osteoclast function. J. Bone Miner. Res. 22 (2007) 1387-1396
27. Gardsvoll H., and Ploug M. Mapping of the vitronectin-binding site on the urokinase receptor: involvement of a coherent receptor interface consisting of residues from both domain I and the flanking interdomain linker region. J. Biol. Chem. 282 (2007) 13561-13572
28. Ghosh S., Johnson J.J., Sen R., Mukhopadhyay S., Liu Y., Zhang F., Wei Y., Chapman H.A., and Stack M.S. Functional relevance of urinary-type plasminogen activator receptor-alpha3beta1 integrin association in proteinase regulatory pathways. J. Biol. Chem. 281 (2006) 13021-13029
29. Gladson C.L., and Cheresh D.A. Glioblastoma expression of vitronectin and the alpha v beta 3 integrin. Adhesion mechanism for transformed glial cells. J. Clin. Invest. 88 (1991) 1924-1932
30. Gomez C., and Hope T.J. The ins and outs of HIV replication. Cell. Microbiol. 7 (2005) 621-626
31. Gu J.M., Johns A., Morser J., Dole W.P., Greaves D.R., and Deng G.G. Urokinase plasminogen activator receptor promotes macrophage infiltration into the vascular wall of ApoE deficient mice. J. Cell Physiol. 204 (2005) 73-82
32. Gyetko M.R., Sud S., Kendall T., Fuller J.A., Newstead M.W., and Standiford T.J. Urokinase receptor-deficient mice have impaired neutrophil recruitment in response to pulmonary Pseudomonas aeruginosa infection. J. Immunol. 165 (2000) 1513-1519
33. Gyetko M.R., Sud S., Sonstein J., Polak T., Sud A., and Curtis J.L. Antigen-driven lymphocyte recruitment to the lung is diminished in the absence of urokinase-type plasminogen activator (uPA) receptor, but is independent of uPA. J. Immunol. 167 (2001) 5539-5542
34. Hayman E.G., Pierschbacher M.D., Ohgren Y., and Ruoslahti E. Serum spreading factor (vitronectin) is present at the cell surface and in tissues. Proc. Natl. Acad. Sci. USA 80 (1983) 4003-4007
35. Hoyer-Hansen G., Behrendt N., Ploug M., Dano K., and Preissner K.T. The intact urokinase receptor is required for efficient vitronectin binding: receptor cleavage prevents ligand interaction. FEBS Lett. 420 (1997) 79-85
36. Huai Q., Mazar A.P., Kuo A., Parry G.C., Shaw D.E., Callahan J., Li Y., Yuan C., Bian C., Chen L., Furie B., Furie B.C., Cines D.B., and Huang M. Structure of human urokinase plasminogen activator in complex with its receptor. Science 311 (2006) 656-659
37. Hynes R.O. Integrins: versatility, modulation, and signaling in cell adhesion. Cell 69 (1992) 11-25
38. Inuzuka S., Ueno T., Torimura T., Tamaki S., Sakata R., Sata M., Yoshida H., and Tanikawa K. Vitronectin in liver disorders: biochemical and immunohistochemical studies. Hepatology 15 (1992) 629-636
39. Jaskiewicz K., Chasen M.R., and Robson S.C. Differential expression of extracellular matrix proteins and integrins in hepatocellular carcinoma and chronic liver disease. Anticancer Res. 13 (1993) 2229-2237
40. Jo M., Thomas K.S., O'Donnell D.M., and Gonias S.L. Epidermal growth factor receptor-dependent and -independent cell-signaling pathways originating from the urokinase receptor. J. Biol. Chem. 278 (2003) 1642-1646
41. Juliano R.L., and Varner J.A. Adhesion molecules in cancer: the role of integrins. Curr. Opin. Cell Biol. 5 (1993) 812-818
42. Jurdic P., Saltel F., Chabadel A., and Destaing O. Podosome and sealing zone: specificity of the osteoclast model. Eur. J. Cell Biol. 85 (2006) 195-202
43. Kanse S.M., Kost C., Wilhelm O.G., Andreasen P.A., and Preissner K.T. The urokinase receptor is a major vitronectin-binding protein on endothelial cells. Exp. Cell Res. 224 (1996) 344-353
44. Kindzelskii A.L., Laska Z.O., Todd III R.F., and Petty H.R. Urokinase-type plasminogen activator receptor reversibly dissociates from complement receptor type 3 (alpha M beta 2′ CD11b/CD18) during neutrophil polarization. J. Immunol. 156 (1996) 297-309
45. Kindzelskii A.L., Eszes M.M., Todd III R.F., and Petty H.R. Proximity oscillations of complement type 4 (alphaX beta2) and urokinase receptors on migrating neutrophils. Biophys. J. 73 (1997) 1777-1784
46. Kjoller L., and Hall A. Rac mediates cytoskeletal rearrangements and increased cell motility induced by urokinase-type plasminogen activator receptor binding to vitronectin. J. Cell Biol. 152 (2001) 1145-1157
47. Kobayashi J., Yamada S., and Kawasaki H. Distribution of vitronectin in plasma and liver tissue: relationship to chronic liver disease. Hepatology 20 (1994) 1412-1417
48. Kugler M.C., Wei Y., and Chapman H.A. Urokinase receptor and integrin interactions. Curr. Pharm. Des. 9 (2003) 1565-1574
49. Lawrence D.A., Berkenpas M.B., Palaniappan S., and Ginsburg D. Localization of vitronectin binding domain in plasminogen activator inhibitor-1. J. Biol. Chem. 269 (1994) 15223-15228
50. Lester R.D., Jo M., Montel V., Takimoto S., and Gonias S.L. uPAR induces epithelial mesenchymal transition in hypoxic breast cancer cells. J. Cell Biol. 178 (2007) 425-436
51. Lindahl T.L., Sigurdardottir O., and Wiman B. Stability of plasminogen activator inhibitor 1 (PAI-1). Thromb. Haemost. 62 (1989) 748-751
52. Linder S., and Aepfelbacher M. Podosomes: adhesion hot-spots of invasive cells. Trends Cell Biol. 13 (2003) 376-385
53. Liu D., Aguirre Ghiso J., Estrada Y., and Ossowski L. EGFR is a transducer of the urokinase receptor initiated signal that is required for in vivo growth of a human carcinoma. Cancer Cell 1 (2002) 445-457
54. Loridon-Rosa B., Vielh P., Cuadrado C., and Burtin P. Comparative distribution of fibronectin and vitronectin in human breast and colon carcinomas. An immunofluorescence study. Am. J. Clin. Pathol. 90 (1988) 7-16
55. Madsen C.D., Ferraris G.M., Andolfo A., Cunningham O., and Sidenius N. uPAR-induced cell adhesion and migration: vitronectin provides the key. J. Cell Biol. 177 (2007) 927-939
56. May A.E., Kanse S.M., Lund L.R., Gisler R.H., Imhof B.A., and Preissner K.T. Urokinase receptor (CD87) regulates leukocyte recruitment via beta 2 integrins in vivo. J. Exp. Med. 188 (1998) 1029-1037
57. Mohri H., and Ohkubo T. How vitronectin binds to activated glycoprotein IIb-IIIa complex and its function in platelet aggregation. Am. J. Clin. Pathol. 96 (1991) 605-609
58. Nakamura I., Pilkington M.F., Lakkakorpi P.T., Lipfert L., Sims S.M., Dixon S.J., Rodan G.A., and Duong L.T. Role of alpha(v)beta(3) integrin in osteoclast migration and formation of the sealing zone. J. Cell Sci. 112 (1999) 3985-3993
59. Nguyen D.H., Hussaini I.M., and Gonias S.L. Binding of urokinase-type plasminogen activator to its receptor in MCF-7 cells activates extracellular signal-regulated kinase 1 and 2 which is required for increased cellular motility. J. Biol. Chem. 273 (1998) 8502-8507
60. Nguyen D.H., Catling A.D., Webb D.J., Sankovic M., Walker L.A., Somlyo A.V., Weber M.J., and Gonias S.L. Myosin light chain kinase functions downstream of Ras/ERK to promote migration of urokinase-type plasminogen activator-stimulated cells in an integrin-selective manner. J. Cell Biol. 146 (1999) 149-164
61. Nguyen D.H., Webb D.J., Catling A.D., Song Q., Dhakephalkar A., Weber M.J., Ravichandran K.S., and Gonias S.L. Urokinase-type plasminogen activator stimulates the Ras/Extracellular signal-regulated kinase (ERK) signaling pathway and MCF-7 cell migration by a mechanism that requires focal adhesion kinase, Src, and Shc. Rapid dissociation of GRB2/Sps-Shc complex is associated with the transient phosphorylation of ERK in urokinase-treated cells. J. Biol. Chem. 275 (2000) 19382-19388
62. Niculescu F., Rus H.G., Porutiu D., Ghiurca V., and Vlaicu R. Immunoelectron-microscopic localization of S-protein/vitronectin in human atherosclerotic wall. Atherosclerosis 78 (1989) 197-203
63. Nielsen B.S., Rank F., Illemann M., Lund L.R., and Dano K. Stromal cells associated with early invasive foci in human mammary ductal carcinoma in situ coexpress urokinase and urokinase receptor. Int. J. Cancer 120 (2007) 2086-2095
64. Nip J., Shibata H., Loskutoff D.J., Cheresh D.A., and Brodt P. Human melanoma cells derived from lymphatic metastases use integrin alpha v beta 3 to adhere to lymph node vitronectin. J. Clin. Invest. 90 (1992) 1406-1413
65. Okano K., Maeba T., Moroguchi A., Ishimura K., Karasawa Y., Izuishi K., Goda F., Usuki H., Wakabayashi H., and Maeta H. Lymphocytic infiltration surrounding liver metastases from colorectal cancer. J. Surg. Oncol. 82 (2003) 28-33
66. Okumura Y., Kamikubo Y., Curriden S.A., Wang J., Kiwada T., Futaki S., Kitagawa K., and Loskutoff D.J. Kinetic analysis of the interaction between vitronectin and the urokinase receptor. J. Biol. Chem. 277 (2002) 9395-9404
67. Ozanne B.W., Spence H.J., McGarry L.C., and Hennigan R.F. Invasion is a genetic program regulated by transcription factors. Curr. Opin. Genet. Dev. 16 (2006) 65-70
68. Ozanne B.W., Spence H.J., McGarry L.C., and Hennigan R.F. Transcription factors control invasion: AP-1 the first among equals. Oncogene 26 (2007) 1-10
69. Preissner K.T. Structure and biological role of vitronectin. Annu. Rev. Cell Biol. 7 (1991) 275-310
70. Price D.T., and Loscalzo J. Cellular adhesion molecules and atherogenesis. Am. J. Med. 107 (1999) 85-97
71. Pytela R., Pierschbacher M.D., and Ruoslahti E. A 125/115-kDa cell surface receptor specific for vitronectin interacts with the arginine-glycine-aspartic acid adhesion sequence derived from fibronectin. Proc. Natl. Acad. Sci. USA 82 (1985) 5766-5770
72. Rabbani S.A., Gladu J., Mazar A.P., Henkin J., and Goltzman D. Induction in human osteoblastic cells (SaOS2) of the early response genes fos, jun, and myc by the amino terminal fragment (ATF) of urokinase. J. Cell Physiol. 172 (1997) 137-145
73. Reilly J.T., and Nash J.R. Vitronectin (serum spreading factor): its localisation in normal and fibrotic tissue. J. Clin. Pathol. 41 (1988) 1269-1272
74. Rijneveld A.W., Levi M., Florquin S., Speelman P., Carmeliet P., and van Der Poll T. Urokinase receptor is necessary for adequate host defense against pneumococcal pneumonia. J. Immunol. 168 (2002) 3507-3511
75. Ross R. Cell biology of atherosclerosis. Annu. Rev. Physiol. 57 (1995) 791-804
76. Ross R. Atherosclerosis - an inflammatory disease. N. Engl. J. Med. 340 (1999) 115-126
77. Salasznyk R.M., Zappala M., Zheng M., Yu L., Wilkins-Port C., and McKeown-Longo P.J. The uPA receptor and the somatomedin B region of vitronectin direct the localization of uPA to focal adhesions in microvessel endothelial cells. Matrix Biol. 26 (2007) 359-370
78. Sawada Y., Tamada M., Dubin-Thaler B.J., Cherniavskaya O., Sakai R., Tanaka S., and Sheetz M.P. Force sensing by mechanical extension of the Src family kinase substrate p130Cas. Cell 127 (2006) 1015-1026
79. Schroeck F., Arroyo de Prada N., Sperl S., Schmitt M., and Viktor M. Interaction of plasminogen activator inhibitor type-1 (PAI-1) with vitronectin (Vn): mapping the binding sites on PAI-1 and Vn. Biol. Chem. 383 (2002) 1143-1149
80. Seiffert D., and Loskutoff D.J. Evidence that type 1 plasminogen activator inhibitor binds to the somatomedin B domain of vitronectin. J. Biol. Chem. 266 (1991) 2824-2830
81. Sidenius N., and Blasi F. Domain 1 of the urokinase receptor (uPAR) is required for uPAR-mediated cell binding to vitronectin. FEBS Lett. 470 (2000) 40-46
82. Sidenius N., and Blasi F. The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy. Cancer Metastasis Rev. 22 (2003) 205-222
83. Sidenius N., Andolfo A., Fesce R., and Blasi F. Urokinase regulates vitronectin binding by controlling urokinase receptor oligomerization. J. Biol. Chem. 277 (2002) 27982-27990
84. Simon D.I., Wei Y., Zhang L., Rao N.K., Xu H., Chen Z., Liu Q., Rosenberg S., and Chapman H.A. Identification of a urokinase receptor-integrin interaction site. Promiscuous regulator of integrin function. J. Biol. Chem. 275 (2000) 10228-10234
85. Stefansson S., Su E.J., Ishigami S., Cale J.M., Gao Y., Gorlatova N., and Lawrence D.A. The contributions of integrin affinity and integrin-cytoskeletal engagement in endothelial and smooth muscle cell adhesion to vitronectin. J. Biol. Chem. 282 (2007) 15679-15689
86. Tang H., Kerins D.M., Hao Q., Inagami T., and Vaughan D.E. The urokinase-type plasminogen activator receptor mediates tyrosine phosphorylation of focal adhesion proteins and activation of mitogen-activated protein kinase in cultured endothelial cells. J. Biol. Chem. 273 (1998) 18268-18272
87. Thiagarajan P., and Kelly K.L. Exposure of binding sites for vitronectin on platelets following stimulation. J. Biol. Chem. 263 (1988) 3035-3038
88. Tomasini-Johansson B.R., Milbrink J., and Pejler G. Vitronectin expression in rheumatoid arthritic synovia - inhibition of plasmin generation by vitronectin produced in vitro. Br. J. Rheumatol. 37 (1998) 620-629
89. van der Pluijm G., Sijmons B., Vloedgraven H., van der Bent C., Drijfhout J.W., Verheijen J., Quax P., Karperien M., Papapoulos S., and Lowik C. Urokinase-receptor/integrin complexes are functionally involved in adhesion and progression of human breast cancer in vivo. Am. J. Pathol. 159 (2001) 971-982
90. Vial E., Sahai E., and Marshall C.J. ERK-MAPK signaling coordinately regulates activity of Rac1 and RhoA for tumor cell motility. Cancer Cell 4 (2003) 67-79
91. Wang Y. The role and regulation of urokinase-type plasminogen activator receptor gene expression in cancer invasion and metastasis. Med. Res. Rev. 21 (2001) 146-170
92. Wei Y., Waltz D.A., Rao N., Drummond R.J., Rosenberg S., and Chapman H.A. Identification of the urokinase receptor as an adhesion receptor for vitronectin. J. Biol. Chem. 269 (1994) 32380-32388
93. Wei Y., Lukashev M., Simon D.I., Bodary S.C., Rosenberg S., Doyle M.V., and Chapman H.A. Regulation of integrin function by the urokinase receptor. Science 273 (1996) 1551-1555
94. Wei Y., Yang X., Liu Q., Wilkins J.A., and Chapman H.A. A role for caveolin and the urokinase receptor in integrin-mediated adhesion and signaling. J. Cell Biol. 144 (1999) 1285-1294
95. Wei Y., Eble J.A., Wang Z., Kreidberg J.A., and Chapman H.A. Urokinase receptors promote beta1 integrin function through interactions with integrin alpha3beta1. Mol. Biol. Cell 12 (2001) 2975-2986
96. Wei Y., Czekay R.P., Robillard L., Kugler M.C., Zhang F., Kim K.K., Xiong J.P., Humphries M.J., and Chapman H.A. Regulation of alpha5beta1 integrin conformation and function by urokinase receptor binding. J. Cell Biol. 168 (2005) 501-511
97. Wei Y., Tang C.H., Kim Y., Robillard L., Zhang F., Kugler M.C., and Chapman H.A. Urokinase receptors are required for alpha 5 beta 1 integrin-mediated signaling in tumor cells. J. Biol. Chem. 282 (2007) 3929-3939
98. Wei C., Moller C.C., Altintas M.M., Li J., Schwarz K., Zacchigna S., Xie L., Henger A., Schmid H., Rastaldi M.P., Cowan P., Kretzler M., Parilla R., Bendayan M., Gupta V., Nikolic B., Kalluri R., Carmeliet P., Mundel P., and Reiser J. Modification of kidney barrier function by the urokinase receptor. Nat. Med. 14 (2008) 55-63
99. Wilcox S.A., Reho T., Higgins P.J., Tominna-Sebald E., and McKeown-Longo P.J. Localization of urokinase to focal adhesions by human fibrosarcoma cells synthesizing recombinant vitronectin. Biochem. Cell Biol. 74 (1996) 899-910
100. Wilcox-Adelman S.A., Wilkins-Port C.E., and McKeown-Longo P.J. Localization of urokinase type plasminogen activator to focal adhesions requires ligation of vitronectin integrin receptors. Cell. Adhes. Commun. 7 (2000) 477-490
101. Xue W., Mizukami I., Todd III R.F., and Petty H.R. Urokinase-type plasminogen activator receptors associate with beta1 and beta3 integrins of fibrosarcoma cells: dependence on extracellular matrix components. Cancer Res. 57 (1997) 1682-1689
102. Zhang F., Tom C.C., Kugler M.C., Ching T.T., Kreidberg J.A., Wei Y., and Chapman H.A. Distinct ligand binding sites in integrin alpha3beta1 regulate matrix adhesion and cell-cell contact. J. Cell Biol. 163 (2003) 177-188
103. Zhou A., Huntington J.A., Pannu N.S., Carrell R.W., and Read R.J. How vitronectin binds PAI-1 to modulate fibrinolysis and cell migration. Nat. Struct. Biol. 10 (2003) 541-544